Goldman Sachs Group Inc. reduced its position in Arbutus Biopharma Corporation (NASDAQ:ABUS) by 33.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 241,676 shares of the biopharmaceutical company’s stock after selling 122,470 shares during the period. Goldman Sachs Group Inc.’s holdings in Arbutus Biopharma Corporation were worth $785,000 at the end of the most recent quarter.

Separately, Renaissance Technologies LLC raised its position in shares of Arbutus Biopharma Corporation by 785.1% in the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 110,499 shares during the last quarter. 66.49% of the stock is currently owned by institutional investors and hedge funds.

Arbutus Biopharma Corporation (ABUS) remained flat at $3.75 during midday trading on Wednesday. The company had a trading volume of 6,052 shares. Arbutus Biopharma Corporation has a 52 week low of $2.35 and a 52 week high of $4.04. The stock’s market cap is $206.35 million. The company’s 50-day moving average is $3.66 and its 200-day moving average is $3.29.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/arbutus-biopharma-corporation-abus-stake-reduced-by-goldman-sachs-group-inc/1494957.html.

A number of brokerages recently weighed in on ABUS. Zacks Investment Research lowered shares of Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Ladenburg Thalmann Financial Services began coverage on shares of Arbutus Biopharma Corporation in a report on Friday, June 2nd. They issued a “buy” rating and a $32.00 price objective for the company. Finally, Chardan Capital restated a “buy” rating on shares of Arbutus Biopharma Corporation in a report on Monday, August 7th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $11.65.

Arbutus Biopharma Corporation Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Want to see what other hedge funds are holding ABUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arbutus Biopharma Corporation (NASDAQ:ABUS).

Institutional Ownership by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.